Want to see HK:1548 full AI Analyst Report?
Top Page
Genscript Biotech
(1548)
Select Model
Select Model
Rating:62Neutral
Price Target:
HK$35.00
▼(-1.35% Downside)
Action:Reiterated
Date:08/21/26
The score is driven primarily by improving operating fundamentals and cash flow, plus a very strong and guidance-raising earnings call. Offsetting these positives are highly volatile net income (negative P/E) and technicals that appear extremely overbought, increasing near-term downside risk despite the broader uptrend.
Positive Factors
Strong growth and expanding LSG margins
LSG combines strong demand growth with operating leverage and margins above 55%. This supports durable cash generation as recurring research workflows, automation and scale improve the economics of serving biopharma customers.
Negative Factors
Highly volatile and currently weak net profitability
Large swings in bottom-line earnings make profitability difficult to forecast and weaken confidence that operating improvements will translate consistently into shareholder returns. The business still needs several periods of normalized earnings to prove durability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong growth and expanding LSG margins
LSG combines strong demand growth with operating leverage and margins above 55%. This supports durable cash generation as recurring research workflows, automation and scale improve the economics of serving biopharma customers.
Read all positive factors
Genscript Biotech (1548) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$75.92B
Dividend Yield0.35%
Average Volume (3M)48.08M
Price to Earnings (P/E)―
Beta (1Y)1.33
Revenue Growth53.48%
EPS Growth-120.02%
CountryHK
Employees6,135
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.25
Shares Outstanding2,200,591,800
10 Day Avg. Volume40,107,205
30 Day Avg. Volume48,079,095
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)3.60
P/FCF Ratio14.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$33.72Price Target Upside-4.97% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)<0.01
Revenue Forecast (FY)HK$889.37M
Genscript Biotech Business Overview & Revenue Model
Company Description
Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassin...
How the Company Makes Money
GenScript makes money primarily by selling products and providing fee-for-service R&D and manufacturing services to third parties. Key revenue streams include: (1) Life-science research products and services: revenue from catalog and custom offeri...
Genscript Biotech Earnings Call Summary
Earnings Call Date:Aug 17, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Mar 24, 2027
Earnings Call Sentiment Positive
Overall the call was strongly positive: the company reported robust top-line growth (USD 404.2M, +27.3%), record adjusted net profit (+203.3% to USD 62.5M), significant margin expansion and raised guidance, while highlighting clear strategic advantages in AI-enabled validation and a strong balance sheet. The main negatives are a still-unprofitable ProBio (though materially improved), Bestzyme's modest growth and widened operating loss, and execution/demand risks tied to the pace of AIDD adoption and scaling protein-side automation. On balance, highlights substantially outweigh lowlights.Positive Updates
Strong Group Revenue Growth
Total revenue reached USD 404.2 million, up 27.3% year-over-year, driven by broad-based demand across segments.
Negative Updates
Bestzyme Slow Growth and Increased Operating Loss
Bestzyme revenue growth was modest at +7.4% YoY and adjusted operating loss widened to USD 1.3 million (from a USD 0.6 million loss in H1 2025), reflecting deliberate investment but near-term profitability pressures.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Group Revenue Growth
Total revenue reached USD 404.2 million, up 27.3% year-over-year, driven by broad-based demand across segments.
Read all positive updates
Company Guidance
Management raised full‑year guidance: Life Science Services revenue growth 25–30% with adjusted gross margin >55% and adjusted operating margin >25%; ProBio revenue growth 25–30% with positive EBITDA expected in 2027; and Bestzyme revenue growth 8–10% with adjusted gross margin >43%. This follows a strong H1 baseline (group revenue US$404.2M, +27.3% YoY; adjusted net profit US$62.5M, +203.3%; group gross profit US$206.7M, +48%); LSG delivered US$319M revenue (+28.8%), adjusted gross profit US$185M (+46.1%) and adjusted operating profit US$94M (+102.8%) with adjusted gross margin 57.8% (55.4% ex U.S. tariff refunds) and operating margin 29.5% (27.1% same basis); ProBio H1 revenue US$61.1M (+34.2%), adjusted gross profit US$8.3M and adjusted EBITDA loss narrowed to US$6.5M (vs. -US$16.8M); Bestzyme H1 revenue US$30.4M (+7.4%) and adjusted gross profit US$13M (+14%). Management also disclosed H1 CapEx US$48.4M and full‑year CapEx ~US$130M, cash ≈US$830M, a 1.5x YoY surge in gene‑to‑protein ROI, and expects AIDD orders to double in H2 as a driver of continued upside.Genscript Biotech Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
72
Positive
Cash Flow
60
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 959.53M | 594.49M | 560.48M | 625.70M | 490.10M |
| Gross Profit | 553.20M | 272.13M | 270.63M | 304.08M | 282.52M |
| EBITDA | 317.61M | 70.04M | 83.50M | -389.04M | -477.27M |
| Net Income | -532.83M | 2.96B | -95.48M | -226.85M | -358.71M |
Balance Sheet | |||||
| Total Assets | 4.85B | 5.28B | 3.39B | 2.55B | 2.23B |
| Cash, Cash Equivalents and Short-Term Investments | 843.01M | 621.18M | 1.93B | 1.46B | 1.41B |
| Total Debt | 258.84M | 723.74M | 416.99M | 349.80M | 156.45M |
| Total Liabilities | 876.30M | 954.91M | 1.34B | 1.18B | 846.17M |
| Stockholders Equity | 3.96B | 4.32B | 1.39B | 1.01B | 1.05B |
Cash Flow | |||||
| Free Cash Flow | 241.69M | -72.27M | -444.62M | -336.40M | -269.83M |
| Operating Cash Flow | 325.52M | 75.65M | -286.91M | -120.29M | -136.79M |
| Investing Cash Flow | -171.95M | -1.46B | -357.73M | -443.30M | -212.55M |
| Financing Cash Flow | -144.89M | 66.52M | 1.07B | 419.32M | 902.14M |
Genscript Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$204.83B | 34.53 | 10.51% | ― | 21.93% | 21.94% | |
68 Neutral | HK$71.46B | 59.67 | 5.86% | 1.07% | 16.62% | >-0.01% | |
62 Neutral | HK$75.92B | -14.38 | -16.23% | 0.35% | 53.48% | -120.02% | |
60 Neutral | HK$2.82B | 14.07 | 4.45% | 0.27% | 7.38% | 7.90% | |
59 Neutral | HK$82.81B | 42.98 | 10.96% | 0.80% | 20.39% | 26.48% | |
58 Neutral | HK$2.57B | 28.94 | 3.02% | ― | 10.32% | 178.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1548
Genscript Biotech
32.00
15.06
88.90%
HK:2269
Wuxi Biologics (Cayman)
47.50
11.50
31.94%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
28.28
5.76
25.55%
HK:1521
Frontage Holdings Corp.
1.18
-0.23
-16.31%
HK:1873
Viva Biotech Holdings
1.33
-1.26
-48.65%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
138.10
44.35
47.31%
Genscript Biotech Corporate Events
Genscript Biotech Clarifies Board Structure and Committee Roles
Aug 16, 2026
Genscript Biotech has detailed the composition of its board of directors, naming Chairman Jiange (Robin) Meng, President Ye (Sally) Wang and other executive directors, alongside six independent non-executive directors drawn from diverse scientific...
Genscript Biotech Posts Strong Core Growth but Reports Interim Loss on Legend Impact
Aug 16, 2026
Genscript Biotech reported strong underlying growth for the six months ended 30 June 2026, with revenue rising 27.3% year-on-year to US$404.2 million and gross profit jumping 48.0% on the same basis. The adjusted net profit reached US$62.5 million...
Genscript Highlights Legend Biotech’s Q2 Results and Cautions Investors
Aug 11, 2026
Genscript Biotech has released a voluntary announcement informing investors that its associate, Legend Biotech Corporation, has filed its second-quarter 2026 financial results and recent business highlights with the U.S. Securities and Exchange Co...
Genscript Biotech Sets August Board Meeting to Approve Interim Results
Aug 5, 2026
Genscript Biotech Corporation has scheduled a board meeting in the United States for 15 August 2026 to review and approve its interim results for the six months ended 30 June 2026. The board will also decide on the publication of these results and...
Genscript Highlights Strong CARVYKTI Sales via Legend Biotech, Urges Investor Caution
Jul 15, 2026
Genscript Biotech announced that its associate Legend Biotech reported preliminary net trade sales of approximately US$657 million for CARVYKTI for the quarter ended 30 June 2026, under a collaboration and license agreement with Janssen Biotech, I...
GenScript Associate Legend Biotech Reports Promising In Vivo CAR-T Data in B-Cell Lymphoma
Jun 14, 2026
GenScript’s associate Legend Biotech has reported first clinical proof-of-concept data for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The dat...
Genscript Biotech Shareholders Approve All Resolutions at 2026 AGM
Jun 5, 2026
Genscript Biotech Corporation reported that all resolutions proposed at its annual general meeting on 5 June 2026 were passed by shareholders by way of poll. All directors attended either in person or via telecommunication, and the company confirm...
Genscript Biotech Grants 14.7 Million RSUs to Strengthen Long-Term Incentives
Jun 4, 2026
Genscript Biotech Corporation is a Cayman Islands–incorporated biotechnology company listed in Hong Kong that focuses on biotechnological research and development services. The group’s operations rely heavily on key scientific talent, ...
Genscript Highlights Legend Biotech’s Early In Vivo CAR-T Data for B-Cell Lymphoma
Jun 2, 2026
Genscript Biotech announced that its associate, Legend Biotech, will present promising preliminary Phase 1 clinical data for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-...
Genscript Highlights Legend Biotech’s New CAR-T Data in Oncology Programs
Jun 1, 2026
Genscript Biotech has announced that its associate Legend Biotech presented first-in-human clinical data for LB2102, an investigational DLL3-targeted CAR-T cell therapy for patients with relapsed or refractory small cell lung cancer and large-cell...
GenScript Associate Legend Biotech to Unveil New CAR-T Data at 2026 ASCO Meeting
May 22, 2026
Legend Biotech, an associate of GenScript Biotech, has announced that it will present new clinical data at the 2026 American Society of Clinical Oncology Annual Meeting, underscoring its ongoing efforts in cutting-edge cancer therapies. The presen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.